🇺🇸·Jan 1, 1970Industry
Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113), a First-in-Class Investigational Targeted Oral Peptide That Selectively Blocks the IL-23 Receptor
Publisher
P
Protagonist Therapeutics
USA
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Protagonist Therapeutics
- Region
- USA
- Scope
- Industry
- Published
- January 1, 1970
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on protagonist-inc.com
Leave the platform to read the original full article on the publisher site.
Source: Protagonist Therapeutics
Scope: Industry
Related coverage
More related coverage
Adial Pharmaceuticals·1d ago
Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing
Adial Pharmaceuticals·1d ago
Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing
Relmada Therapeutics·1d ago
Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program
eXoZymes·4d ago